**Members Obtain Free CE Credits from JCP Articles!** 

**Pharmacokinetic Drug Interactions of Apatinib With Rifampin and Itraconazole**

March 2018 – *The Journal of Clinical Pharmacology*

***Why is this article important to you?***

Small-molecule pharmacotherapeutic agents represent an emerging category with important utility in disease-state management, including applications in the field of oncology. Safe and efficacious use of these agents requires an understanding of drug interaction potential, and a recognition of pharmacodynamic and pharmacokinetic implications. This activity provides insight relative to the effects of induction and inhibition on the pharmacokinetic profile of apatinib. Such information will further inform the approach to the oncology patient, deemed a candidate for small-molecule therapy.



**ACPE Accreditation Statement**

The American College of Clinical Pharmacology is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

**UAN:** 0238-0000-18-005-H01-P – ACPE 1 Contact Hours

**Activity Type:** Knowledge-based **Format:** Home-study **Target Audience**: ‘P’

**ACCME Accreditation Statement**

****The American College of Clinical Pharmacology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**ACCME Designation Statement**

The Accreditation Council for Continuing Medical Education designates this journal CE activity for 1 *AMA PRA Category 1TM* credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**Disclosures:**

 Article Selection: Joseph Bertino, PharmD, Editor-in-Chief, JCP; Owner, Bertino Consulting, has nothing to disclose.

 Designer: Steven Crosby, MA, BSP, Assistant Dean, Associate Professor of Pharmacy Practice, MCPHS University, who developed the continuing education portion of this activity (target audience, goals and objectives and questions with solutions), has nothing to disclose related to this educational topic.

 Reviewer: Michael Jann, PharmD, Professor, Pharmacotherapy, Univ of North Texas System Coll of Pharmacy, has nothing to disclose related to this educational topic.

**Target Audience**

The target audience for this activity includes physicians, clinical pharmacologists, pharmacists, and clinical researchers. This activity offers substantial insight for both oncologists and researchers focusing on drug-drug interaction potentials.

**Goal and Objectives**

After completing this activity, the learner will be able to:

1. Identify isozymes involved in the metabolic fate of apatinib.
2. Describe the pharmacokinetic implications of combining apatinib with enzyme inducers and inhibitors.
3. Identify factors that contribute to variations in kinetic parameters secondary to a drug-drug interaction.

**Requirements to Receive Credit**

In order to receive CE credit, the learner must register for the educational activity, study the provided journal article, complete the online post-event assessment (test) with a score or 75% or higher, complete an online evaluation, and print their certificate.

**Schedule & Fees**

JCP monthly Journal CE articles are generally released on the 2nd Tuesday of each month. They are priced in packages of Jan - Dec for each year. Packages are available at no cost to ACCP Members and $75/calendar year to Non-members. Once you register, you have access to all of the articles for the calendar year.

**Acknowledgement of Financial Support**

No financial support was received for this educational activity.

**Home Study Initial Release and Expiration Dates**

**Date of Issuance:**  March 1, 2018

**Expiration Date:**  March 1, 2021

**Online Location:**

<https://accp1.org/Members/Continuing_Education/Journal_CE/ACCP1/4Continuing_Education/Journal_CE.aspx>